[1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. - 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-220010.1093/eurheartj/ehw12827206819]Search in Google Scholar
[2. Morrow DA, de Lemos JA. Benchmarks for the assessment of cardiovascular biomarkers. Circulation. 2007;115(8):949–95210.1161/CIRCULATIONAHA.106.68311017325253]Search in Google Scholar
[3. Correale M, Monaco I, Brunetti ND, di Biase M, Metra M, Nodari S, et al. Redefining biomarkers in heart failure. 2018;23(2):237-25310.1007/s10741-018-9683-2]Search in Google Scholar
[4. Iaconetti C, Gareri C, Polimeni A, Indolfi C. Non-Coding RNAs: The “Dark Matter” of Cardiovascular Pathophysiology. Int J Mol Sci. 2013;14(10):19987-2001810.3390/ijms141019987382159924113581]Search in Google Scholar
[5. Islas JF, Moreno-Cuevas JE. A MicroRNA Perspective on Cardiovascular Development and Diseases: An Update. Int J Mol Sci. 2018;19(7):2075-209010.3390/ijms19072075607375330018214]Search in Google Scholar
[6. Tian J, An X, Niu L. Role of microRNAs in cardiac development and disease. Exp Ther Med. 2017;13(1):3-810.3892/etm.2016.3932524477928123459]Search in Google Scholar
[7. Sárközy M, Kahán Zs, and Csont T. A myriad of roles of miR-25 in health and disease. Oncotarget. 2018;9(30):21580-2161210.18632/oncotarget.24662594037629765562]Search in Google Scholar
[8. Wojciechowska A, Braniewska A, Kozar-Kamińska K. MicroRNA in cardiovascular biology and disease. Adv Clin Exp Med. 2017;26(5):865–87410.17219/acem/6291529068585]Search in Google Scholar
[9. Wang J, Liew OW, Chen Y-T. Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis. Int J Mol Sci. 2016;17(5):749-77010.3390/ijms17050749488157027213331]Search in Google Scholar
[10. de Gonzalo-Calvo D, Iglesias-Gutiérrez E, Llorente-Cortés V. Epigenetic Biomarkers and Cardiovascular Disease: Circulating MicroRNAs. Rev Esp Cardiol (Engl Ed). 2017;70(9):763-76910.1016/j.recesp.2017.02.027]Search in Google Scholar
[11. Schulte C, Karakas M, Zeller T. microRNAs in cardiovascular disease – clinical application. Clin Chem Lab Med. 2017;55(5):687–70410.1515/cclm-2016-057627914211]Search in Google Scholar
[12. Yan H, Ma F, Li Y, Zhangv Y, Wang C, Qiu D. miRNAs as biomarkers for diagnosis of heart failure. Medicine. 2017;96(22):22-3210.1097/MD.0000000000006825545969828562533]Search in Google Scholar
[13. Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo MR, Siniscalchi M. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J of Heart Fail. 2013;15(11):1277–128810.1093/eurjhf/hft08823736534]Search in Google Scholar
[14. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, Kok WE, Pinto YM. MiR423-5p As a Circulating Biomarker for Heart Failure. Circ Res. 2010;106(6):1035-103910.1161/CIRCRESAHA.110.21829720185794]Search in Google Scholar
[15. Schmitter D, Voors AA, van der Harst P. HFpEF vs. HFrEF: can microRNAs advance the diagnosis? Eur J of Heart Fail. 2015;17(4):351–35410.1002/ejhf.259]Search in Google Scholar
[16. Nair N, Gupta S, Collier IX, Gongora E, Vijayaraghavan K. Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF? Int. J. of Cardiology 2014;175(3):395–39910.1016/j.ijcard.2014.06.027]Search in Google Scholar
[17. Oliveira-Carvalho V, Carvalho VO, Silva MM, Guimarães GV, Bocchi EA. MicroRNAs: a new paradigm in the treatment and diagnosis of heart failure? Arq Bras Cardiol. 2012;98(4):362-36910.1590/S0066-782X2012000400011]Search in Google Scholar
[18. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685-689.10.1038/nature0430316258535]Search in Google Scholar
[19. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980-98410.1038/nature0751119043405]Search in Google Scholar
[20. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124(14):1537-154710.1161/CIRCULATIONAHA.111.030932335355121900086]Search in Google Scholar